These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

965 related items for PubMed ID: 11051136

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study.
    Gupta AK, Onychomycosis Combination Therapy Study Group.
    J Drugs Dermatol; 2005; 4(4):481-5. PubMed ID: 16004022
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The dermatopharmacologic profile of ciclopirox 8% nail lacquer.
    Bohn M, Kraemer K.
    J Am Podiatr Med Assoc; 2000; 90(10):491-4. PubMed ID: 11107709
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis.
    Jaiswal A, Sharma RP, Garg AP.
    Indian J Dermatol Venereol Leprol; 2007; 73(6):393-6. PubMed ID: 18032857
    [Abstract] [Full Text] [Related]

  • 30. Ciclopirox nail lacquer and podiatric practice.
    Gupta AK, Malkin KF.
    J Am Podiatr Med Assoc; 2000; 90(10):502-7. PubMed ID: 11107711
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis.
    Gupta AK.
    J Am Podiatr Med Assoc; 2002 May; 92(5):272-86. PubMed ID: 12015408
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.
    Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, Herz-Ruelas ME, Jones TM, Jarratt MT, Pollak RA, Zane LT.
    J Drugs Dermatol; 2014 Sep; 13(9):1124-32. PubMed ID: 25226015
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Development of ciclopirox nail lacquer with enhanced permeation and retention.
    Thapa RK, Choi JY, Go TG, Kang MH, Han SD, Jun JH, Son MW, Yong CS, Kim JO.
    Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 49.